company background image
OCY logo

Oncimmune Holdings BST:OCY Stock Report

Last Price

€0.22

Market Cap

€18.2m

7D

20.7%

1Y

-39.3%

Updated

27 Mar, 2024

Data

Company Financials

OCY Stock Overview

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally.

OCY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Oncimmune Holdings plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncimmune Holdings
Historical stock prices
Current Share PriceUK£0.22
52 Week HighUK£0.45
52 Week LowUK£0.15
Beta1.14
1 Month Change-9.02%
3 Month Change-16.54%
1 Year Change-39.34%
3 Year Change-89.63%
5 Year Change-75.60%
Change since IPO-85.33%

Recent News & Updates

Recent updates

Shareholder Returns

OCYDE BiotechsDE Market
7D20.7%1.2%2.5%
1Y-39.3%34.7%7.0%

Return vs Industry: OCY underperformed the German Biotechs industry which returned 37% over the past year.

Return vs Market: OCY underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is OCY's price volatile compared to industry and market?
OCY volatility
OCY Average Weekly Movement7.2%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: OCY's share price has been volatile over the past 3 months.

Volatility Over Time: OCY's weekly volatility has decreased from 12% to 7% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2015n/aMartin Gouldstonehttps://www.oncimmune.com

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Oncimmune Holdings plc Fundamentals Summary

How do Oncimmune Holdings's earnings and revenue compare to its market cap?
OCY fundamental statistics
Market cap€18.17m
Earnings (TTM)-€7.18m
Revenue (TTM)€1.34m

13.5x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OCY income statement (TTM)
RevenueUK£1.15m
Cost of RevenueUK£360.00k
Gross ProfitUK£792.00k
Other ExpensesUK£6.94m
Earnings-UK£6.15m

Last Reported Earnings

Aug 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.083
Gross Margin68.75%
Net Profit Margin-533.94%
Debt/Equity Ratio786.9%

How did OCY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.